EFFICACY, MECHANISMS AND SAFETY OF SGLT2 INHIBITORS IN KIDNEY TRANSPLANT RECIPIENTS: "INFINITI"
- Registry ID
- INFINITI2019
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- DR. SUNITA K.S. SINGH
- Start date
- 2020-12-01
- Last update
- 2021-01-29
Conditions
- TYPE 2 DIABETES
- KIDNEY TRANSPLANTATION
Related clinical trials
- A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ELECOGLIPRON COMPARED WITH ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS (ELUMINATE-2)
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY RO7795068 ADMINISTERED TO PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES
- EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED, ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED TRIAL (VESPER-5)
- A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, RANDOMIZED PHASE 2 TRIAL EVALUATING THE EFFICACY AND SAFETY OF FELZARTAMAB IN RECIPIENTS OF KIDNEY TRANSPLANTS WITH LATE ISOLATED MICROVASCULAR INFLAMMATION (MVI) - (TRANSPIRE0
- EFFICACY AND SAFETY OF CAGRILINTIDE FOR WEIGHT MANAGEMENT IN PARTICIPANTS
WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (RENEW 2)
- A PHASE I/II, RANDOMISED, SINGLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-ASCENDING-DOSE
STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF
AZD9550 MONOTHERAPY AND CO-ADMINISTRATION OF AZD9550 AND AZD6234 IN PARTICIPANTS
LIVING WITH OBESITY AND OVERWEIGHT WITH OR WITHOUT TYPE 2 DIABETES MELLITUS
View on source registry